Pindolol
Pindolol Information

About Pindolol

Pindolol is oral, nonselective, ß-receptor antagonist with intrinsic sympathomimetic activity (ISA) (i.e., partial agonist activity). Pindolol is the ß-blocker with the highest degree of ISA and nonselective antagonist qualities. The effect of ISA, as with ß-blockade in general, can be selective or nonselective in nature. The partial agonist potential of Pindolol is greater for ß 2- than ß1-receptors, a characteristic that renders the drug a "vasodilatory" ß-blocker. It was approved by the FDA in September 1982 for the treatment of hypertension. Like other ß-adrenergic antagonists, it competes with adrenergic neurotransmitters (e.g., catecholamines) for binding at sympathetic receptor sites, similar to propranolol.

Indications

Pindolol is primarily indicated in conditions like Angina, Cardiac arrhythmia, Hypertension, Supraventricular tachycardia.

Contraindication

Pindolol is contraindicated in conditions like Bronchospasm,Haemorrhage,Heart block,Bradycardia.

Side Effects

Pindolol produces potentially life-threatening effects which include Cardiac failure, Hypoglycemia, Hypoglycemia, Bronchospasm, Ischemic heart disease. which are responsible for the discontinuation of Pindolol therapy.The symptomatic adverse reactions produced by Pindolol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Insomnia, Nervousness, Muscle cramps, Edema, Muscle pain, nervousness.

Warnings

Pindolol should be used with caution in diabetic patients and patients with liver and kidney impairments.

High Risk Groups

Drug should not be given to Paediatrics, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.